feed rss
decorazione
Star Alliance

SYMPOSIUM 33

 

ROOM ANADOLU    16:15 - 17:45

 


Late breaking clinical trials - 2

 

 

Chairs: Markus Ketteler, Coburg, Germany
             Christoph Wanner, Würzburg, Germany

 

 

The selective type A endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetes and nephropathy
Dick de Zeeuw, Groningen, The Netherlands
 
The use of PTH-lowering drugs is associated with improved survival in heemodialysis patients. Results from COSMOS
Jorge B. Cannata-Andía, Oviedo, Spain
 
Safety and efficacy of PA21, a novel iron-based phosphate binder, in patients with ESRD and hyperphosphatemia: long-term results
Jürgen Floege, Aachen, Germany
  
Effect of cinacalcet use on all-cause mortality: parallel analyses in ARO incident observational European hemodialysis population and in EVOLVE trial
Jürgen Floege, Aachen, Germany
  
Oral paricalcitol treatment on left ventricular mass and function in chronic kidney disease patients with cardiac hypertrophy (OPERA study): a randomized controlled trial
Angela Y.M. Wang, Hong Kong SAR, China
 

back to the timetable

final programme "day by day" - may 18 - 21, 2013

today